Switzerland - based gene - editing biotech firm CRISPR Therapeutics has filed with the US SEC to list its IPO on the Nasdaq with a view to raising $ 90 m in the public market , having already raised millions in private funding . The company booked around $ 2 ##m in sales for the year to end June , but posted operating losses of close to $ 30 m in H1 2016 . Basel, Switzerland-based CRISPR Therapeutics (although much of its work is done in Massachusetts), has already made millions in private funding, but is now looking to join this group of publicly traded gene editing biotechs, saying in its SEC filing posted late Friday that it wants raise up to $90 million, and plans to list under the ticker $CRSP on the Nasdaq. CRISPR 's move follows other acquisitions of notable biotech start - ups , Editas and Intellia . The firm already operates a joint venture with Germany ’s Bayer ( Casebia Therapeutics ) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin - based programmes .
Switzerland - based gene - editing biotech firm CRISPR Therapeutics has filed with the US SEC to list its IPO on the Nasdaq with a view to raising $ 90 m in the public market , having already raised millions in private funding . The company booked around $ 2 ##m in sales for the year to end June , but posted operating losses of close to $ 30 m in H1 2016 . CRISPR 's move follows other acquisitions of notable biotech start - ups , Editas and Intellia . The firm already operates a joint venture with Germany ’s Bayer ( Casebia Therapeutics ) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin - based programmes .